Subtype
Kidney and Ureter Neoplasm
CI-CAN-00001051Explore in graph →
Non-malignant518 active trials17 approved drugs81 evidence items
- NCIt
- C7514
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001051Explore in graph →
Clinical trials
2,409 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02526511 | Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors | completed | N/A | 75 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05361434 | A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults(CaboCombo) | completed | — | 311 | IpsenINDUSTRY | 8 | Jun 1, 2026 |
| clinicaltrials |
| NCT00600496 | A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | completed | Phase 1 | 140 | AstraZenecaINDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT02231749 | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) | completed | Phase 3 | 1,096 | Bristol-Myers SquibbINDUSTRY | 28 | May 27, 2026 | clinicaltrials |
| NCT03260894 | Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) | completed | Phase 3 | 129 | Incyte CorporationINDUSTRY | 20 | May 22, 2026 | clinicaltrials |
| NCT04687969 | Multimodal Machine Learning Characterization of Solid Tumors | completed | — | 50 | Ciprian Catana, MD, PhDOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04846920 | A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018) | completed | Phase 1 | 29 | Merck Sharp & Dohme LLCINDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT06898632 | KidneyCare Cohort Study (KCC-S)(KCC-S) | completed | — | 161 | University of UtahOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT00898365 | Study of Kidney Tumors in Younger Patients | completed | — | 8,000 | Children's Oncology GroupNETWORK | 7 | May 18, 2026 | clinicaltrials |
| NCT01334073 | Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors(EVAX) | completed | Phase 1 | 19 | University Hospital, BordeauxOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04146064 | Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response | completed | — | 190 | University Health Network, TorontoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04987203 | Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma | completed | Phase 3 | 343 | AVEO Pharmaceuticals, Inc.INDUSTRY | 16 | May 8, 2026 | clinicaltrials |
| NCT03229083 | Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma | completed | N/A | 21 | University of RochesterOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT02535533 | SLM + Axitinib for Clear Cell RCC | completed | Phase 1 / Phase 2 | 45 | Mohammed MilhemOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07568444 | Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3) | completed | Phase 2 | 120 | University of Southern CaliforniaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06056505 | Virtual Interactive 3D Modelling to Improve Outcomes in Robotic-Assisted Partial Nephrectomy(3DPN) | completed | N/A | 370 | University of LeipzigOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT02121730 | Identification of Risk Factors Associated With Neoplastic Complications After Renal Transplantation in Nord-Pas de Calais , Normandy and Picardy Regions(FRISC) | completed | — | 2,500 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06059014 | Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer(PRadR) | completed | Phase 1 / Phase 2 | 6 | Centre Leon BerardOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06138496 | Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC | completed | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT00814021 | Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain | completed | Phase 2 | 21 | Institut Claudius RegaudOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04028245 | A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma(SPARC-1) | completed | Early Phase 1 | 17 | Columbia UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04416646 | Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma(ZEBRA) | completed | — | 100 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06020651 | Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside(VICKI) | completed | N/A | 39 | Institut Mutualiste MontsourisOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT03841149 | Volume 3D_US Kidney(VolUS3D) | completed | — | 53 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03798626 | Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | completed | Phase 1 | 167 | Novartis PharmaceuticalsINDUSTRY | 15 | Apr 1, 2026 | clinicaltrials |
| NCT02555748 | Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma(SUP-R) | completed | Phase 4 | 47 | Institut Claudius RegaudOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04960059 | NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts | completed | — | 24 | The Christie NHS Foundation TrustOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07004426 | Symptomatic and Incidental RCC Detection(KIDCaD) | completed | — | 1,000 | Charles University, Czech RepublicOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03142334 | Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) | completed | Phase 3 | 994 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Mar 10, 2026 | clinicaltrials |
| NCT02184416 | Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting(ADONIS) | completed | — | 554 | PfizerINDUSTRY | 8 | Feb 27, 2026 | clinicaltrials |
| NCT07436416 | Circulating and Urinary Exosomal miRNA as Predictors of Treatment Response in Advanced Kidney Cancer(EXO-RENAL2) | completed | N/A | 91 | Institute of Oncology LjubljanaOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07413120 | Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery | completed | Phase 3 | 40 | Incheon St.Mary's HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07406646 | Circulating and Urinary Exosomal miRNA in Advanced Kidney Cancer (EXO-RENAL1)(EXO-RENAL1) | completed | N/A | 91 | Institute of Oncology LjubljanaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT01625351 | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | completed | Phase 1 | 23 | St. Jude Children's Research HospitalOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03707574 | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study | completed | — | 64 | National Cancer Institute (NCI)NIH | 2 | Feb 4, 2026 | clinicaltrials |
| NCT02853331 | Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) | completed | Phase 3 | 861 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 2, 2026 | clinicaltrials |
| NCT00625755 | A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 40 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT06840548 | A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer(OncoCAIX) | completed | Phase 1 | 20 | Philogen S.p.A.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07315100 | Navigated Partial Nephrectomy | completed | N/A | 20 | The Netherlands Cancer InstituteOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04601129 | Advantage of a Fast-recovery Protocol for Minimally Invasive Kidney Surgery(RREIN) | completed | — | 60 | University Hospital, LilleOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT04501913 | Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes | completed | — | 22 | City of Hope Medical CenterOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT02404584 | The Pharmacokinetic Variability of Sunitinib in Patients With Metastatic Renal Cancer(GenCInibs-Suni) | completed | — | 43 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05579847 | Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy | completed | — | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04704219 | Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)(KEYNOTE-B61) | completed | Phase 2 | 160 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Dec 3, 2025 | clinicaltrials |
| NCT05377632 | Comparing Two Different Approaches in Robotic-Assisted Renal Surgery(PIONEER-OPT) | completed | N/A | 40 | Lukas J HefermehlOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 19 | CRISPR Therapeutics AGINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07232927 | Evaluation of Hemostatic Agents in Partial Nephrectomy(HEMOSTA-PN) | completed | N/A | 150 | Ankara UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06345183 | Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients | completed | — | 327 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 6, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jun 2, 2026source: clinicaltrials